Guillemette E. Benoist
Deventer, OV, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Less Is More: Optimized pharmacotherapy with improved coNtinuity of CarE in hospitaLized oLder peOple (LIMONCELLO): study protocol of a cluster randomized controlled trial.
Journal: BMC geriatrics
Published: November 29, 2024
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer.
Journal: European urology oncology
Published: January 14, 2024
A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone.
Journal: Biomedical chromatography : BMC
Published: November 29, 2023
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.
Journal: Clinical pharmacokinetics
Published: April 18, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 28, 2022
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Journal: British journal of clinical pharmacology
Published: June 21, 2021
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance.
Journal: British journal of clinical pharmacology
Published: April 08, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
Journal: Molecular oncology
Published: November 13, 2020
An update on extravasation: basic knowledge for clinical pharmacists.
Journal: European journal of hospital pharmacy : science and practice
Published: November 13, 2019
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients.
Journal: Cancer chemotherapy and pharmacology
Published: October 20, 2019
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
Journal: Clinical chemistry
Published: September 06, 2019
Last Updated: 09/26/2026